Published on
May 27, 2025
Novel CRS Prevention Therapy Granted FDA Orphan Drug Designation
The FDA has granted orphan drug designation (ODD) to POLB 001. POLB 001 is an oral preventative therapy for bispecific T-cell engager (BiTE) therapy-induced cytokine release syndrome (CRS). The first patient is expected to be dosed with POLB 001 in a phase …
Source:
Targeted Oncology
-
Pending
